Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma

Running Title: Expanded access to COVID-19 convalescent plasma

Jonathon W. Senefeld^{1†}, Ph.D., Patrick W. Johnson^{2†}, B.S., Katie L. Kunze^{3†}, Ph.D., Noud van Helmond^{4†}, M.D., Stephen A. Klassen¹, Ph.D., Chad C. Wiggins¹, Ph.D., Katelyn A. Bruno⁵, Ph.D., Michael A. Golafshar³, M.S., Molly M. Petersen³, B.S., Matthew R. Buras³, M.S., Allan M. Klompas¹, M.B., B.Ch., B.A.O., Matthew A. Sexton¹, M.D., Juan C. Diaz Soto¹, M.D., Sarah E. Baker¹, Ph.D., John R.A. Shepherd¹, M.D., Nicole C. Verdun⁶, M.D., Peter Marks⁶, M.D., Ph.D., Camille M. van Buskirk⁷, M.D., Jeffrey L. Winters⁷, M.D., James R. Stubbs⁷, M.D., Robert F. Rea⁸, M.D., Vitaly Herasevich¹, M.D., Ph.D., Emily R. Whelan⁵, B.S., Andrew J. Clayburn¹, B.S., Kathryn F. Larson⁸, M.D., Juan G. Ripoll¹, M.D., Kylie J. Andersen¹, B.S., Matthew N.P. Vogt¹, M.D., Joshua J. Dennis¹, B.S., Riley J. Regimbal¹, B.S., Philippe R. Bauer⁹, M.D., Ph.D., Janis E. Blair¹⁰, M.D., Katherine Wright¹¹, BA, Joel T. Greenshields¹², MS, Nigel S. Paneth^{13†}, M.D., M.P.H., DeLisa Fairweather^{5†}, Ph.D., R. Scott Wright^{8,14†}, M.D., Arturo Casadevall^{15†}, M.D., Ph.D., Rickey E. Carter^{2†}, Ph.D., Michael J. Joyner^{1†}, M.D.

AFFILIATIONS

¹Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

²Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida, United States of America

³Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona, United States of America

⁴Department of Anesthesiology, Cooper Medical School of Rowan University, Cooper University Health Care, Camden, New Jersey, United States of America

⁵Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, United States of America

⁶Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America

⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America

⁸Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

⁹Department of Internal Medicine, Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, Minnesota, United States of America

¹⁰Department of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, United States of America

¹¹School of Sustainability, Arizona State University, Tempe, Arizona, United States of America

¹²Department of Kinesiology, Indiana University, Bloomington, Indiana, United States of America

¹³Departments of Epidemiology and Biostatistics and Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan, United States of America

¹⁴Department of Human Research Protection Program, Mayo Clinic, Rochester, Minnesota, United States of America

¹⁵Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America

[†]These authors have contributed equally to this work.

Abstract

Background

The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19). While randomized clinical trials were in various stages of development and enrollment, there was an urgent need for widespread access to potential therapeutic agents particularly for vulnerable racial and ethnic minority populations who were disproportionately affected by the pandemic. The objective of this study is to report on the demographic, geographic, and chronological access to COVID-19 convalescent plasma in the US via the EAP.

Methods and findings

Mayo Clinic served as the central IRB for all participating facilities and any US physician could participate as local physician–principal investigator. Registration occurred through the EAP central website. Blood banks rapidly developed logistics to provide convalescent plasma to hospitalized patients with COVID-19. Demographic and clinical characteristics of all enrolled patients in the EAP were summarized. Temporal trends in access to COVID-19 convalescent plasma were investigated by comparing daily and weekly changes in EAP enrollment in response to changes in infection rate on a state level. Geographical analyses on access to convalescent plasma included assessing EAP enrollment in all national hospital referral regions as well as assessing enrollment in metropolitan and less populated areas which did not have access to COVID-19 clinical trials.

From April 3 to August 23, 2020, 105,717 hospitalized patients with severe or life-threatening COVID-19 were enrolled in the EAP. A majority of patients were older than 60 years of age (57.8%), male (58.4%), and overweight or obese (83.8%). There was substantial inclusion of minorities and underserved populations, including 46.4% of patients with a race other than White, and 37.2% of patients were of Hispanic ethnicity. Severe or life-threatening COVID-19 was present in 61.8% of patients and 18.9% of patients were mechanically ventilated at time of convalescent plasma infusion. Chronologically and geographically, increases in enrollment in the EAP closely followed confirmed infections across all 50 states. Nearly all national hospital referral regions enrolled patients in the EAP, including both in metropolitan and less populated areas.

Conclusions

The EAP successfully provided widespread access to COVID-19 convalescent plasma in all 50 states, including for underserved racial and ethnic minority populations. The efficient study design of the EAP may serve as an example framework for future efforts when broad access to a treatment is needed in response to a dynamic disease affecting demographic groups and areas historically underrepresented in clinical studies.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19), spread rapidly across the United States (US) after confirmation of the first case of COVID-19 in the US in December 2019 and January 2020 [1]. By March of 2020 in the Northeast region of the US, community transmission was occurring in major metropolitan areas and hospitals became overwhelmed with admissions for severe or life-threatening COVID-19 [1]. Although most infected persons have few or no symptoms despite high SARS-CoV-2 viral loads [2], a smaller group of persons develop hypoxemia and severe COVID-19 leading to hospitalization with supplemental oxygen support [3]. Severe cases of COVID-19 can lead to respiratory failure, which is among the leading causes of death in persons with COVID-19 [4].

The cornerstone of treatment for patients with COVID-19 was symptomatic and supportive management [5]. Because there was a dearth of evidence supporting the efficacy of COVID-19 therapeutic strategies during the early stages of this public health emergency, immunomodulatory agents and antivirals, represented promising strategies that were anticipated to provide benefit to patients with COVID-19 [6, 7]. Passive immunotherapy using convalescent plasma or serum had been used previously to treat acute respiratory tract infections [8-10], including severe acute respiratory syndrome coronavirus 1 infection (SARS-CoV-1) [11], and early studies suggested potential efficacy of convalescent plasma in the treatment of COVID-19 [12-14].

In late March and early April of 2020, COVID-19 convalescent plasma began to be administered to patients under single-patient emergency investigational new drug (eIND)

applications while randomized clinical trials of COVID-19 convalescent plasma were in various stages of development and enrollment. For example, one institution in New York City had 45 eIND applications submitted to and approved by the US Food and Drug Administration (FDA) in a two-week period in late March 2020 [15]. The single-patient eIND application process requires substantial administrative support from local institutions and the US FDA and limits widespread and high-volume access to convalescent plasma, particularly for underserved and racial and ethnic minority populations, who were disproportionately affected by the COVID-19 pandemic [16, 17]. Additionally, clinical trials often have inclusion criteria that are restricted to a specific geographical region or disease status (e.g. hospitalized, but not severe patients) and have exclusion criteria (e.g. prisoners or recipients of solid organ transplant). Thus, inherently, more traditional regulatory pathways for obtaining access to COVID-19 convalescent plasma (eIND or clinical trials) result in limited access to convalescent plasma and may potentially limit the ability to comprehensively study the safety of convalescent plasma for the treatment of COVID-19.

To provide access to a COVID-19 treatment and provide a framework for standardized safety data collection, Mayo Clinic initiated the Expanded Access Program (EAP) for COVID-19 convalescent plasma. The primary objective of the EAP was to provide access to convalescent plasma for hospitalized patients in the US with severe or life-threatening COVID-19 [18]. The EAP started as a national registry approved to enroll 5,000 patients, but due to a national demand for COVID-19 plasma, enrollment goals were extended in collaboration with the US Food and Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) with the aim for the EAP to

become a broad national program obviating the need for individual patient INDs. We herein assess the extent to which the EAP was successful in terms of providing access to COVID-19 convalescent plasma by presenting demographic, geographic, and chronological characteristics of enrollment in the EAP alongside publicly available data of state-level trends in COVID-19.

Methods

As described previously [19-21], the EAP was a national registry for hospitalized patients with COVID-19. Collaborative support was provided by the US BARDA and FDA; funding to support the study infrastructure and study-related costs at participating sites was provided under contract from BARDA. Mayo Clinic served as the academic research organization coordinating the national registry. The Mayo Clinic Institutional Review Board (IRB), the central IRB for the registry, approved the protocol (IRB #20-0033412, NCT#: NCT04338360), all amendments, and provided regulatory oversight for all sites and investigators. The principal investigator (M.J.J.) was the regulatory sponsor. A Data and Safety Monitoring Board oversaw the safety analyses and advised the regulatory sponsor and the Mayo Clinic IRB on risk.

Patients

Patients were eligible for enrollment in the EAP if they were: aged 18 years or older, hospitalized with a laboratory confirmed diagnosis of or suspected/probable infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and either had or were judged by a healthcare provider to be at high risk of progression to severe or life-threatening COVID-19. Severe COVID-19 was defined by one or more of the following:

dyspnea, respiratory frequency $\geq 30/\text{min}$, blood oxygen saturation $\leq 93\%$, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300 , lung infiltrates $> 50\%$ within 24 to 48 hours of hospital admission. Life-threatening COVID-19 was defined as one or more of the following: respiratory failure, septic shock, and multiple organ dysfunction or failure. To maximize access to COVID-19 convalescent plasma, no exclusion criteria were used, thereby, enabling access to vulnerable adult populations who may not be eligible for clinical trials, including pregnant women and prisoners.

Enrollment

All hospitals and acute care facilities in the US and its territories, and any physician licensed in the US, were allowed to register for participation provided they agreed to adhere to the online available treatment protocol [18], as well as US FDA and state regulations. All patient registration was facilitated through the central study website [22]. A single consent form, available in eight languages, was used by all participating sites. Informed consent was obtained from the patient or a legally authorized representative prior to enrollment, except for patients in whom an emergency consent was utilized. Criteria for emergency consent were consistent with the federal regulation governing emergency consent [23]. COVID-19 convalescent plasma transfusate and convalescent plasma donors details have been described elsewhere [19-21].

Study data

Demographic and clinical characteristics of enrolled patients were collected using the Research Electronic Data Capture system (REDCap, v.9.1.15 – v10.0.33 Vanderbilt University, Nashville, TN) [24, 25]. REDCap is US Health Insurance Portability and

Accountability Act (HIPAA) compliant and the US FDA authorized its use in the EAP [20, 21]. The EAP was expeditiously established and implemented to provide access to a potential therapeutic for COVID-19 at a time when no satisfactory therapies for COVID-19 were available. To maximize access in the context of stress on clinical staff at participating sites during the COVID-19 pandemic, the online case reporting forms were designed to optimize convenience. Race (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White) and ethnicity (Hispanic or Latino, Not Hispanic or Latino) were reported into categories by site personnel consistent with guidelines provided by the US Office of Management and Budget [26].

The database was updated as needed to fulfill the requirements of the EAP IRB and data collection requirements of BARDA. As the original goal of data collection was to determine safety, updates were needed to capture additional data as enrollment expanded and the study progressed. Enrollment into the EAP was stopped after the FDA issued an emergency use authorization (EUA) for COVID-19 convalescent plasma on August 23rd, 2020. Data clarification requests were sent to participating investigators as needed until the database was locked to further data changes on December 16th, 2020. The study protocol, case report forms with completion instructions, and informed consent form are publicly available on the study website [22], archived by the US Library of Congress.

COVID-19 epidemiological data sources

In order to contextualize whether the patients enrolled in the EAP were reflective of the US population, race and ethnicity data of each state and US territories were retrieved

from the US Census Bureau [27], using the same race and ethnic categories that were collected in the EAP. COVID-19-confirmed infection rates per day for each US state were obtained from the New York Times database [28]. Hospital referral regions are regional healthcare markets defined by where the majority of residents within that region have their hospitalization stays. The 306 hospital referral regions in the US were retrieved from the Dartmouth Atlas of Health Care. Metropolitan and less populated US region data were obtained from US Census Bureau data [27] and the 2010 Office of Management and Budget Standards that define metropolitan and micropolitan areas based on statistical assessments [29]. Micropolitan areas were defined as areas with a population of at least 10,000 and less than 50,000 residents. The US regions of Northeast, Southeast, Midwest, Southwest, and West were delineated using commonly used regions [30]. Characteristics of US hospitals were retrieved from American Hospital Directory [31] and the Centers for Medicare and Medicaid [32]. The potential limitations of the data sources are described in the discussion.

Statistical Considerations

To provide a comprehensive report of the enrollment data on the EAP program descriptive statistics are presented for demographic and clinical variables of interest. To examine enrollment in the EAP over time, dot plots were used to show the number of enrollments, for each US state individually and aggregated by region by day of the study. Additionally, EAP enrollment was compared to the number of confirmed COVID-19 cases per state over the duration of the study. During the window of EAP enrollment, a moving 7-day average was calculated for daily enrollments and COVID-19 cases within each state that enrolled more than 10 patients in total in the EAP. To compare and visualize relative

patterns, these averages were scaled between 0 (lowest cases/enrollments) and 1 (peak cases/enrollments) and overlaid on a geo-faceted graph. The geo-faceted graph contains one cell for each US state and is placed at approximately the same location on the graph as the corresponding geographical location. Differences in geographic access to convalescent plasma through the EAP were assessed by examining enrollment across micropolitan and metropolitan areas and the number of hospitals enrolling patients in each hospital referral region in the United States. All data were processed using R version 3.6.2.

Results

Patient Characteristics

From April 3rd to August 23rd, 2020, 105,717 hospitalized patients with severe or life-threatening COVID-19 were enrolled in the EAP and ~95,000 patients were transfused with COVID-19 convalescent plasma. The EAP halted enrollment forthwith after the US FDA issued an emergency use authorization (EUA) for COVID-19 convalescent plasma, citing that the totality of scientific evidence indicated that convalescent plasma was safe [20, 21] and a potentially promising therapeutic treatment on August 23, 2020 [33]. This authorization enabled physicians to use COVID-19 convalescent plasma without requesting IND permission and obviated the need for access to convalescent plasma via the EAP.

Enrolled patients' demographic characteristics including age, gender, race, ethnicity, and other clinical variables at time of transfusion are shown in **Table 1**. A majority of patients were older than 60 years of age (57.8%), male (58.4%), overweight or obese (83.8%),

and had never smoked (69.7%). There was substantial inclusion of minorities and underserved populations, including 46.4% of patients with a race other than White, and 37.2% of patients were of Hispanic ethnicity. Pre-existing conditions present among enrolled patients are displayed in **Supplemental Table 1**. Of those patients enrolled, 61.8% had severe or life-threatening COVID-19, 42.3% were in the ICU, and 18.9% received mechanical ventilation at time of transfusion. A small proportion of patients (3.9%) had no form of hospital respiratory support prior to infusion. A large percentage of patients had severe risk factors of dyspnea (75.7%), oxygen saturation $\leq$ 93% (75.0%), and acute respiratory failure (60.6%). Patients were also prescribed steroids (65.7%), azithromycin (49.0%) and remdesivir (37.6%) during their hospital stay. The median number of days between diagnosis of COVID-19 and the first transfusion was 4 days (interquartile range, 2 – 8 days), and nearly half of transfused patients (45.0%) received convalescent plasma within 3 days of COVID-19 diagnosis, which often occurred during hospital admission.

Table 1. Characteristics of Patients with COVID-19 who enrolled in the US Expanded Access Program to convalescent plasma.

Baseline Data	
	<i>number/total number (percent)</i>
Age at Enrollment (years)	
18 to 39	9,630/105,717 (9.1)
40 to 59	34,968/105,717 (33.1)
60 to 69	26,305/105,717 (24.9)
70 to 79	21,585/105,717 (20.4)
80 or older	13,229/105,717 (12.5)
Gender	
Female	43,544/105,717 (41.2)
Male	61,761/105,717 (58.4)
Intersex	157/105,717 (0.1)
Transgender	144/105,717 (0.1)
Prefer not to disclose	111/105,717 (0.1)

Baseline Data	
	<i>number/total number (percent)</i>
Weight Status	
Underweight	1,528/104,046 (1.5)
Normal Weight	15,313/104,046 (14.7)
Overweight	28,524/104,046 (27.4)
Obese	58,681/104,046 (56.4)
Race	
American Indian and Alaska Native alone	1,434/105,715 (1.4)
Asian alone	3,432/105,715 (3.2)
Black alone	19,225/105,715 (18.2)
Native Hawaiian and Other Pacific Islander alone	605/105,715 (0.6)
White alone	56,687/105,715 (53.6)
Other or Unknown	23,849/105,715 (22.6)
Two or more races	483/105,715 (0.5)
Ethnicity	
Hispanic/Latino	39,335/105,717 (37.2)
Not Hispanic/Latino	66,382/105,717 (62.8)
Enrollment Month	
April	8,719/105,717 (8.2)
May	15,873/105,717 (15.0)
June	17,965/105,717 (17.0)
July	39,321/105,717 (37.2)
August	23,839/105,717 (22.5)
Smoking Status	
Current smoker	1,690/32,831 (5.1)
Past smoker	8,250/32,831 (25.1)
Never smoked	22,891/32,831 (69.7)
Transfusion Status	
Transfused	94,788/105,717 (89.7)
Plasma Not Ordered/Given	8,177/105,717 (7.7)
Unreported	2,752/105,717 (2.6)
Current severe or life-threatening COVID-19	65,336/105,717 (61.8)
Highest level of hospital respiratory support prior to transfusion	
None	3,619/93,776 (3.9)
Oxygen supplementation	35,137/93,776 (37.5)
Non-Invasive Positive-Pressure Ventilation NIPPV	36,454/93,776 (38.9)
Mechanical ventilation/intubation	18,273/93,776 (19.5)
Extra Corporeal Membrane Oxygenation (ECMO)	293/93,776 (0.3)
Intensive Care Unit (ICU) care prior to infusion	39,929/94,383 (42.3)
Mechanical Ventilation prior to infusion	17,864/94,328 (18.9)
Severe Risk Factors	
Dyspnea	49,486/65,336 (75.7)
Respiratory frequency $\geq$ 30/min	25,520/65,336 (39.1)
Blood oxygen saturation $\leq$ 93%	48,979/65,336 (75.0)

Baseline Data	
	<i>number/total number (percent)</i>
PaO ₂ :FiO ₂ ratio < 300	16,541/65,336 (25.3)
Lung infiltrates > 50% within 24 to 48 hours	24,389/65,336 (37.3)
Respiratory failure	39,617/65,336 (60.6)
Septic shock	4,622/65,336 (7.1)
Multiple organ dysfunction or failure	5,831/65,336 (8.9)
Medications during hospital stay	
ARB	2,942/43,805 (6.7)
Ace Inhibitor	3,752/43,805 (8.6)
Azithromycin	21,470/43,805 (49.0)
Remdesivir	16,460/43,805 (37.6)
Steroids	28,764/43,805 (65.7)
Chloroquine	84/43,805 (0.2)
Hydroxychloroquine	7,802/43,805 (17.8)
Census Region	
Midwest	14,896/105,717 (14.1)
Northeast	11,557/105,717 (10.9)
South	58,285/105,717 (55.1)
West	20,748/105,717 (19.6)
Other	231/105,717 (0.2)
Micro/Metropolitan	
Metropolitan	100,633/105,717 (95.2)
Micropolitan	4,412/105,717 (4.2)
None	672/105,717 (0.6)
Rural Referral Center	
	16,566/104,534 (15.8)
Sole Community Hospital	
	4,520/104,534 (4.3)
Part of a Health System	
	89,234/104,534 (85.4)
Major Teaching Hospital (member of COTH)	
	26,012/101,511 (25.6)
University Affiliated	
	56,689/104,534 (54.2)

Geospatial Trends in Enrollment

Patients were enrolled from each state in the US, the District of Columbia, and the US territories of Puerto Rico, and the US Virgin Islands (**Table 2**). A large percentage of patients were enrolled in the Southern region of the US (55.1%) and most patients enrolled in a hospital within a metropolitan area (95.2%) that was part of a health system (85.4%) and/or was university affiliated (54.2%).

Table 2. Tabular summaries of patient enrollment in the US Expanded Access Program (EAP) to convalescent plasma and US COVID-19 cases during the EAP enrollment period, stratified by US state or territory in alphabetical order.

State	EAP Summaries			Population and COVID+ Ratios		
	Enrolling Sites	Enrolled Patients	Transfused Patients	COVID+ Cases / Enrollment	Enrollments / 10,000 people	Enrollments / 1,000 COVID+ Cases
Alabama	35	2,408	2,016	51.9	4.9	19.3
Alaska	3	59	58	100.5	0.8	9.9
Arizona	41	3,961	3,680	50.6	5.4	19.8
Arkansas	16	597	498	101.5	2.0	9.9
California	236	11,874	10,076	59.2	3.0	16.9
Colorado	27	646	628	84.3	1.1	11.9
Connecticut	23	1,022	928	48.3	2.9	20.7
Delaware	4	372	366	45.9	3.8	21.8
District of Columbia	9	349	278	38.4	4.9	26.0
Florida	158	12,553	11,206	49.0	5.8	20.4
Georgia	74	5,424	4,921	46.0	5.1	21.7
Hawaii	8	320	316	25.6	2.3	39.1
Idaho	10	156	131	202.5	0.9	4.9
Illinois	92	3,137	2,709	73.5	2.5	13.6
Indiana	64	1,746	1,610	53.7	2.6	18.6
Iowa	35	1,299	1,222	49.8	4.1	20.1
Kansas	23	703	609	61.0	2.4	16.4
Kentucky	40	884	836	56.8	2.0	17.6
Louisiana	44	1,548	1,351	92.0	3.3	10.9
Maine	9	62	58	67.5	0.5	14.8
Maryland	42	1,812	1,592	58.9	3.0	17.0
Massachusetts	37	907	790	133.2	1.3	7.5
Michigan	61	1,071	875	97.0	1.1	10.3
Minnesota	35	1,052	1,008	71.5	1.9	14.0
Mississippi	19	1,380	1,313	59.3	4.6	16.9
Missouri	41	1,347	1,262	62.9	2.2	15.9
Montana	8	133	127	54.3	1.2	18.4
Nebraska	18	509	471	66.9	2.6	15.0
Nevada	19	1,303	1,128	52.2	4.2	19.2
New Hampshire	8	127	92	54.0	0.9	18.5
New Jersey	66	2,768	2,452	62.0	3.1	16.1
New Mexico	14	433	415	57.7	2.1	17.3
New York	110	4,492	4,146	79.1	2.3	12.6
North Carolina	56	1,769	1,627	94.1	1.7	10.6
North Dakota	7	226	216	51.7	3.0	19.4
Ohio	77	2,184	2,007	55.2	1.9	18.1
Oklahoma	27	1,415	1,324	41.0	3.6	24.4
Oregon	17	320	290	81.2	0.8	12.3

EAP Summaries				Population and COVID+ Ratios		
State	Enrolling Sites	Enrolled Patients	Transfused Patients	COVID+ Cases / Enrollment	Enrollments / 10,000 people	Enrollments / 1,000 COVID+ Cases
Pennsylvania	90	1,930	1,702	68.9	1.5	14.5
Puerto Rico	31	222	184	148.3	0.7	6.7
Rhode Island	9	248	242	86.2	2.3	11.6
South Carolina	38	3,970	3,530	29.6	7.7	33.7
South Dakota	6	427	409	31.3	4.8	31.9
Tennessee	51	2,592	2,444	57.6	3.8	17.4
Texas	221	19,363	17,507	32.8	6.7	30.4
Virgin Islands	2	9	6	123.2		8.1
Utah	8	592	573	86.4	1.8	11.6
Vermont	1	1	1	1,303.0	0.0	0.8
Virginia	51	1,747	1,480	68.2	2.0	14.7
Washington	34	942	881	76.6	1.2	13.1
West Virginia	11	102	88	98.6	0.6	10.1
Wisconsin	62	1,195	1,100	66.3	2.1	15.1
Wyoming	4	9	9	411.6	0.2	2.4

Patients were enrolled by 12,879 healthcare providers from 2,722 hospitals and acute care facilities across the US, **Figure 1**. COVID-19 convalescent plasma was provided by 317 blood banks. The median number of participants per site was 22 (range, 1 to 1,175). While 2,722 sites were registered, 490 (18.0%) enrolled no patients, 732 (26.9%) enrolled between 1 and 10 patients, and 1,500 (55.1%) enrolled more than 10 patients. Registered sites encompassed nearly all hospital referral regions in the US, **Figure 2**. Sites participation occurred both in metropolitan and non-metropolitan areas and from different hospital types ranging from community hospitals to major teaching hospitals, **Table 1 and Supplemental Table 2**.

Figure 1. Participation in the US Expanded Access Program (EAP) to convalescent plasma. Choropleth map displaying the number of cumulatively enrolled patients in the EAP within each state of the US and participating territories, with lower enrollment values displayed in a lighter shade and higher enrollment values displayed in a darker shade of blue. Registered acute care facilities are represented as filled yellow circles, with larger circles indicating greater number of registered facilities within the county. Blood collection centers are represented as filled red diamonds. All sites with registered patients were included. The choropleth map does not display Guam or the Northern Mariana Islands.

Figure 2. Participation of acute care facilities in the US Expanded Access Program (EAP) to convalescent plasma stratified by US hospital referral region. Choropleth map displaying the number of participating acute care facilities which enrolled patients in the EAP within each hospital referral region—a geographical regions which represent a catchment region of patients who get health care at similar facilities. Lower numbers of participating acute care facilities are displayed in a lighter hue of blue and higher numbers of participating acute care facilities are displayed in a darker hue of blue. Hospital referral regions with zero participating acute care facilities are displayed in grey. Hospital referral regions are not defined in US territories; thus, the choropleth map does not display data from Puerto Rico, the US Virgin Islands, Guam or the Northern Mariana Islands.

Recognizing the disproportionate effects of the COVID-19 pandemic on minority communities [17], the EAP sought widespread access to convalescent plasma including in all representations populations. Patient enrollment stratified by race and ethnicity groups is displayed in **Figure 3**, relative to 100,000 people from US census.

Figure 3. Patient enrollment in the US Expanded Access Program (EAP) stratified by race and ethnic group, relative to 100,000 people from US census per age, race and ethnicity. The length of each colored bar is proportional to the number of patients enrolled in the US EAP within the identified age group (years) and race or ethnicity category. The patient enrollment values are presented relative to analogous categorical data retrieved from the US Census Bureau.

Temporal Trends in Enrollment

Enrollment in the EAP for convalescent plasma per US state on each day of the EAP is displayed in **Figure 4**. The individual state and regional aggregates show clear trends of when COVID-19 was surging during EAP enrollment. **Figure 5** presents enrollment over time together with the number of active COVID-19 cases per US state. Chronologically, increases in enrollment in the EAP closely followed the individual state infection rate. Enrollment in the EAP per 1,000 confirmed COVID-19 cases varied from 0.8 (Vermont) to 39.1 (Hawaii) patients across US states. The proportion that each US region contributed to the total enrollment into the EAP varied throughout the program and **Figure 6** displays proportional enrollment into the EAP across time by US geographical region, COVID-19 disease severity, and mechanical ventilation status prior to COVID-19 convalescent plasma transfusion.

Figure 4. Daily patient enrollment in the US Expanded Access Program (EAP). Each circle represents one day in which at least one patient was enrolled, within the indicated US state or region. Blue circles represent daily US state enrollments and yellow circles represent daily US region enrollments. Larger circles represent a greater number of daily enrollments within the indicated US state or region. Nil patient enrollments on a given day are not represented with a symbol. States are ordered alphabetically by US region, and an aggregate for each region is also represented.

Figure 5. Daily rates of COVID-19-confirmed infections and patient enrollment in the US Expanded Access Program (EAP). Chronological line charts represent the daily number of state-wide COVID-19-confirmed infections and EAP patient enrollment sequentially arranged in a geofaceted depiction of the US. Daily rates are presented as a moving average across seven days, scaled between 0 (least cases/enrollments) and 1 (most cases/enrollments) for any day in each state. Vertical, dashed grey lines represent the start date of the EAP (April 3rd, 2020). Values in the lower left corner of each panel indicate the scaling factor between the two plots (cases/enrollments), which approximates the number of COVID-19 cases that contributed to one enrollment in the EAP. EAP enrollment data are not presented for Vermont or Wyoming because total enrollments were not greater than 10 patients.

Figure 6. Daily patient enrollment in the US Expanded Access Program (EAP) relative to each US geographical region. Stacked area chart displaying daily rates of patient enrollment in the EAP as a proportion of the sum total daily enrollment within each of four US geographical regions, two categories of COVID-19 disease severity (severe or life-threatening), and dichotomous representation of mechanical ventilation status prior to COVID-19 convalescent plasma transfusion. Only patients that received a COVID-19 convalescent plasma transfusion are included in the rightmost panel dichotomized by mechanical ventilation status.

Discussion

Principal findings

The US EAP successfully provided access to COVID-19 convalescent plasma to over 105,000 patients, of which nearly 95,000 patients were transfused with convalescent plasma over the course of five months. Access to convalescent plasma closely kept pace with increases in confirmed US COVID-19 infections per state over time and there was substantial inclusion of vulnerable racial and ethnic minority populations. Geographically, enrollment in the EAP occurred in all US States, the District of Columbia, and the US territories of Puerto Rico, and the U.S. Virgin Islands. Patients were enrolled from all but five of US national hospital referral regions, and substantial enrollment occurred in both metropolitan and non-metropolitan areas.

Demographic characteristics of patients enrolled in the EAP

Demographic characteristics of the complete enrolled EAP cohort showed substantial enrollment among patients over the age of 60 (57.8%), male patients (58.4%), patients of African American or Black race (18.2%), and patients of Hispanic or Latino ethnicity (37.2%). African American or Black race and Hispanic or Latino ethnicity make up 13.4% and 18.5% of the US population, respectively [27]. Previous studies have found that older [34, 35], male [35], African American or Black race [34, 36, 37], and Hispanic or Latino [37] individuals are at higher risk of hospitalization for severe or life-threatening COVID-19. The presented enrollment results from the EAP highlight that this program was able to provide access to COVID-19 convalescent plasma to demographic groups that have suffered the largest disease burden from the US COVID-19 epidemic.

Chronological and Geographical characteristics

Peak enrollment in the EAP per day closely tracked the number of cases reported by state as the COVID-19 epidemic developed. Enrollment during April and May, 2020 was high in Northeastern states, whereas in July and August enrollment peaked in the Southeast and Southwest regions of mainland US, in line with the development of 'hotspots' in these regions over time [38]. An increase in enrollment in Midwestern states was observed during August 2020, and this trend was also closely associated with an increase in confirmed COVID-19 cases in that region. Although there was widespread participation across US states and territories, there were less than 10 patients enrolled in both Vermont ($n = 1$) and Wyoming ($n=9$), representing a small fraction of the total COVID-19 cases in those states. Given that there were no registered clinical trials involving COVID-19 convalescent plasma in these two states during the time of the EAP,

there may have been regulatory or administrative barriers to participation in trials involving experimental therapeutics for COVID-19.

Implications for future pandemics

The success of the EAP in providing rapid access to convalescent plasma in metropolitan and regional areas of the US that might not otherwise have had access to therapy provides a framework for future efforts when broad access to a treatment is needed in response to an infectious disease outbreak. In this regard it is noteworthy that given that clinical trials were limited to only a few institutions, that most patients treated with plasma would have had no access without the EAP or single-patient eINDs. The high use of convalescent plasma within the EAP indicates a high level of acceptance for this therapy by patients and frontline physicians despite the absence of high-quality data for its clinical efficacy. The EAP design was particularly effective in providing access to a potentially effective treatment in minority demographic groups and rural areas that are often underrepresented in US randomized controlled trials [39, 40].

Methodological considerations

The US EAP for COVID-19 convalescent plasma aimed to provide access to a treatment possibly providing benefit, while randomized clinical trials were in various stages of development and enrollment. This enrollment report focused on the primary aim of the EAP of providing access to COVID-19 convalescent plasma; whereas, analyses on potential efficacy from EAP data have been presented elsewhere [19, 41].

Limitations

Numerous challenges were encountered during the development and implementation of this national registry. Given the constraints on health care resources during the COVID-19 pandemic [42], this national registry used a modern design with creative solutions to overcome the epidemiological and contextual challenges of the pandemic [43]. These creative solutions included a central academic IRB for oversight, streamlined registration for sites and physicians, simple online data collection forms, robust support center accessible via email or telephone, limited patient exclusion criteria, limited restrictions on concomitant therapies, and no initiation or monitoring site visits. Several important limitations resulted from this design, however, including adjustments in required data collection elements which were inversely related to the number of cases of COVID-19 in the US, unavailable data due to abridged data collection forms, and missing data due to the nature of a national registry. Additionally, the EAP was designed to provide access to convalescent plasma at hospitals and acute care facilities that were not already part of a clinical trial or did not have the infrastructure to support complex clinical trials. This registry also did not require training of the local investigators or study team members. The design of this national registry provided widespread access to convalescent plasma and easy to complete data collection forms during a worldwide pandemic. This pragmatic approach did not ensure the highest quality of data nor completeness of data.

Conclusions

The EAP provided rapid and broad access to convalescent plasma throughout the US and some US territories and was effective at providing therapy for demographic groups that were severely affected by COVID-19. Over time, the EAP provided access to convalescent plasma in response to sudden and exponential changes in SARS-CoV-2

infection rates. Data gathered from the EAP established the COVID-19 convalescent plasma was generally safe [20, 21] and provided key efficacy data that were an important component of the scientific evidence considered by the US FDA in the decision to issue an EUA [19] for convalescent plasma in the treatment of hospitalized adults with COVID-19. Hence, this program established that it is possible to obtain relevant and actionable safety and efficacy data during pandemic conditions. The efficient study design of the EAP may serve as an example for future efforts when broad access to a treatment is needed in response to a rapidly developing infectious disease providing access in areas typically underrepresented in clinical studies and thereby allowing capture of demographic groups that are often poorly represented in clinical trials.

Article Information

Disclaimer: The views and opinions expressed in this manuscript are those of the authors and do not reflect the official policy or position of the US Department of Health and Human Services and its agencies including the Biomedical Research and Development Authority and the Food and Drug Administration, as well as any agency of the U.S. government. Assumptions made within and interpretations from the analysis are not reflective of the position of any US government entity.

Author Contributions: Drs. Joyner and Carter had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosures: United Health Group, Millennium Pharmaceuticals, and Octapharma USA Inc., supported this project. No other disclosures were reported.

Funding/Support: This project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096. Additionally, this study was supported in part by National Center for Advancing Translational Sciences (NCATS) grant UL1TR002377, National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 (to MJJ) and grant 1F32HL154320 (to JWS), Natural Sciences and Engineering Research Council of Canada (NSERC) PDF-532926-2019 (to SAK), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5T32DK07352 (to CCW), National Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356, R21 AI152318 and R21 AI154927 (to DF), R01 AI152078 9 (to AC), National Heart Lung and Blood Institute RO1 HL059842 (to AC), National Institute on Aging (NIA) U54AG044170 (to SEB), Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health Group, National Basketball Association (NBA), Millennium Pharmaceuticals, Octapharma USA, Inc, and the Mayo Clinic.

Data Access Statement: Individual participant data underlying the results reported in this publication, along with a data dictionary, will be made available to approved investigators for secondary analyses following the completion of the objectives of the United States Expanded Access Program to COVID-19 convalescent plasma. Limited and de-identified data sets will be deposited into a research data repository and may be shared with investigators under controlled access procedures as approved by the Mayo Clinic Institutional Review Board. A scientific committee will review requests for the conduct of protocols approved or determined to be exempt by an Institutional Review

427 Board. Requestors will be required to sign a data use agreement. Data sharing must be
428 compliant with all applicable Mayo Clinic policies.

References

1. The L. COVID-19 in the USA: a question of time. *Lancet* (London, England). 2020;395(10232):1229. Epub 2020/04/20. doi: 10.1016/s0140-6736(20)30863-1. PubMed PMID: 32305080; PubMed Central PMCID: PMC7162627.
2. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. *Ann Intern Med*. 2020;173(5):362-7. Epub 2020/06/04. doi: 10.7326/M20-3012. PubMed PMID: 32491919; PubMed Central PMCID: PMC7281624.
3. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020. Epub 2020/04/23. doi: 10.1001/jama.2020.6775. PubMed PMID: 32320003; PubMed Central PMCID: PMC7177629.
4. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. *JAMA Intern Med*. 2020. Epub 2020/07/16. doi: 10.1001/jamainternmed.2020.3596. PubMed PMID: 32667668; PubMed Central PMCID: PMC7364338.
5. Fan E, Beitler JR, Brochard L, Calfee CS, Ferguson ND, Slutsky AS, et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? *Lancet Respir Med*. 2020;8(8):816-21. Epub 2020/07/10. doi:

449 10.1016/S2213-2600(20)30304-0. PubMed PMID: 32645311; PubMed Central PMCID:
450 PMCPMC7338016.

451 6. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al.
452 Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv.
453 2020:2020.07.29.20162917. Epub 2020/11/04. doi: 10.1101/2020.07.29.20162917.
454 PubMed PMID: 33140056; PubMed Central PMCID: PMCPMC7605561.

455 7. Ripoll Sanz J, van Helmond N, Senefeld JW, Wiggins CC, Klassen SA, Baker SE,
456 et al. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in
457 COVID-19. Clinical Microbiology Newsletter. 2021;ahead of print.

458 8. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark
459 back: passive immunotherapy for influenza and other serious infections. Crit Care Med.
460 2010;38(4 Suppl):e66-73. Epub 2010/02/16. doi: 10.1097/CCM.0b013e3181d44c1e.
461 PubMed PMID: 20154602.

462 9. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and
463 development of passive antibody therapy. Antimicrob Agents Chemother.
464 1994;38(8):1695-702. Epub 1994/08/01. doi: 10.1128/aac.38.8.1695. PubMed PMID:
465 7985997; PubMed Central PMCID: PMCPMC284624.

466 10. Casadevall A, Scharff MD. Return to the past: the case for antibody-based
467 therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150-61. Epub 1995/07/01.

doi: 10.1093/clinids/21.1.150. PubMed PMID: 7578724; PubMed Central PMCID:
PMCPMC7197598.

11. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent
plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*.
2005;24(1):44-6. Epub 2004/12/24. doi: 10.1007/s10096-004-1271-9. PubMed PMID:
15616839; PubMed Central PMCID: PMCPMC7088355.

12. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill
Patients With COVID-19 With Convalescent Plasma. *Jama*. 2020;323(16):1582-9. doi:
10.1001/jama.2020.4783.

13. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent
Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-
threatening COVID-19: A Randomized Clinical Trial. *Jama*. 2020;324(5):460-70. Epub
2020/06/04. doi: 10.1001/jama.2020.10044. PubMed PMID: 32492084; PubMed Central
PMCID: PMCPMC7270883 COVID-19 testing. Dr Wu reports consulting for Verax
Medical and Grifols, receiving royalties from UptoDate and AABB, and being a volunteer
visiting professor and receiving travel support for giving medical education from the
Chinese Institute of Blood Transfusion. No other disclosures were reported.

14. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al.
Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.

487 Am J Pathol. 2020;190(8):1680-90. Epub 2020/05/31. doi: 10.1016/j.ajpath.2020.05.014.

488 PubMed PMID: 32473109; PubMed Central PMCID: PMCPMC7251400.

489 15. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al.

490 Convalescent plasma treatment of severe COVID-19: a propensity score-matched control

491 study. Nat Med. 2020;26(11):1708-13. Epub 2020/09/17. doi: 10.1038/s41591-020-1088-

492 9. PubMed PMID: 32934372.

493 16. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 - A

494 Dangerous Convergence for Black Americans. N Engl J Med. 2020;383(12):e77. Epub

495 2020/07/25. doi: 10.1056/NEJMp2023616. PubMed PMID: 32706952; PubMed Central

496 PMCID: PMCPMC7747672.

497 17. Evans MK. Covid's Color Line - Infectious Disease, Inequity, and Racial Justice. N

498 Engl J Med. 2020;383(5):408-10. Epub 2020/07/30. doi: 10.1056/NEJMp2019445.

499 PubMed PMID: 32726526.

500 18. Joyner MJ. Expanded Access to Convalescent Plasma for the Treatment of

501 Patients with COVID-19. Rochester, MN, US.2020 [updated 08/03/2020; cited 2020

502 10/23/2020]. 1.0:[Available from: <https://www.uscovidplasma.org/physicians-protocol>.

503 19. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al.

504 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. New

505 England Journal of Medicine. 2021. doi: 10.1056/NEJMoa2031893.

- 506 20. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al.
507 Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo
508 Clin Proc. 2020;95(9):1888-97. Epub 2020/08/31. doi: 10.1016/j.mayocp.2020.06.028.
509 PubMed PMID: 32861333; PubMed Central PMCID: PMC7368917.
- 510 21. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al.
511 Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest.
512 2020;130(9):4791-7. Epub 2020/06/12. doi: 10.1172/JCI140200. PubMed PMID:
513 32525844; PubMed Central PMCID: PMC7456238.
- 514 22. Mayo Clinic. USCovidPlasma. Rochester, MN, US.2020 [cited 2020 10/23/2020].
515 Available from: <https://www.uscovidplasma.org/>.
- 516 23. US Food and Drug Administration. Code of Federal Regulations Title 21 - Part 50
517 Section 50.23. 2019.
- 518 24. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
519 consortium: Building an international community of software platform partners. J Biomed
520 Inform. 2019;95:103208. Epub 2019/05/13. doi: 10.1016/j.jbi.2019.103208. PubMed
521 PMID: 31078660; PubMed Central PMCID: PMC7254481.
- 522 25. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
523 electronic data capture (REDCap)--a metadata-driven methodology and workflow
524 process for providing translational research informatics support. J Biomed Inform.

525 2009;42(2):377-81. Epub 2008/10/22. doi: 10.1016/j.jbi.2008.08.010. PubMed PMID:
526 18929686; PubMed Central PMCID: PMCPMC2700030.

527 26. OFFICE OF MANAGEMENT AND BUDGET. Revisions to the Standards for the
528 Classification of Federal Data on Race and Ethnicity. Federal Register; 1997. p. 58782.

529 27. U.S. Census Bureau. Population Estimates 2018. Available from:
530 <https://www2.census.gov/programs-surveys/popest/datasets/2010-2018/counties/asrh/>.

531 28. The New York Times. Coronavirus US Cases New York City: The New York Times
532 Company; 2020. Available from:
533 <https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html>.

534 29. Office of Management and Budget. Standards for Delineating Metropolitan
535 and Micropolitan Statistical Areas; Notice Federal Register; 2010. p. 37249-52.

536 30. O'Connor SP. United States Regions Washington DC: National Geographic
537 Society 2012 [01/14/2021]. Available from:
538 <https://www.nationalgeographic.org/maps/united-states-regions/>.

539 31. American Hospital Directory. Hospital Profiles 2020 [01/14/2021]. Available from:
540 <https://www.ahd.com/search.php>.

- 541 32. CMS. Provider of Services Baltimore: Centers for Medicare & Medicaid Services;
542 2020. Available from: [https://www.cms.gov/Research-Statistics-Data-and-](https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Provider-of-Services)
543 [Systems/Downloadable-Public-Use-Files/Provider-of-Services](https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Provider-of-Services).

- 544 33. Hilton DM. Letter of authorization Silver Spring: US Food & Drug Administration;
545 2020 [01/14/2021].

- 546 34. Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J, et al.
547 Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 -
548 Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):545-50. Epub
549 2020/05/08. doi: 10.15585/mmwr.mm6918e1. PubMed PMID: 32379729; PubMed
550 Central PMCID: PMCPMC7737948 Journal Editors form for disclosure of potential
551 conflicts of interest. James M. Blum reports personal fees from Clew Medical, outside the
552 submitted work. No other potential conflicts of interest were disclosed.

- 553 35. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of Hospitalized Adults
554 With COVID-19 in an Integrated Health Care System in California. Jama.
555 2020;323(21):2195-8. Epub 2020/04/25. doi: 10.1001/jama.2020.7202. PubMed PMID:
556 32329797; PubMed Central PMCID: PMCPMC7182961 National Institutes of Health
557 (R35GM128672) during the conduct of the study. No other disclosures were reported.

- 558 36. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality
559 among Black Patients and White Patients with Covid-19. The New England journal of

560 medicine. 2020;382(26):2534-43. Epub 2020/05/28. doi: 10.1056/NEJMsa2011686.
561 PubMed PMID: 32459916; PubMed Central PMCID: PMCPMC7269015.

562 37. Karaca-Mandic P, Georgiou A, Sen S. Assessment of COVID-19 Hospitalizations
563 by Race/Ethnicity in 12 States. JAMA Intern Med. 2021;181(1):131-4. Epub 2020/08/18.
564 doi: 10.1001/jamainternmed.2020.3857. PubMed PMID: 32804192; PubMed Central
565 PMCID: PMCPMC7432276 the University of Minnesota, Office of Academic Clinical
566 Affairs and grants from United Health Foundation during the conduct of the study;
567 personal fees from Tactile Medical, Precision Health Economics, and Sempre Health; and
568 grants from the Agency for Healthcare Research and Quality, American Cancer Society,
569 National Institute for Health Care Management, National Institute on Drug Abuse, and
570 National Institutes of Health outside the submitted work. Dr Georgiou reported receiving
571 personal fees from HealthGrades outside the submitted work. No other disclosures were
572 reported.

573 38. Oster AM, Kang GJ, Cha AE, Beresovsky V, Rose CE, Rainisch G, et al. Trends
574 in Number and Distribution of COVID-19 Hotspot Counties - United States, March 8-July
575 15, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(33):1127-32. Epub 2020/08/21. doi:
576 10.15585/mmwr.mm6933e2. PubMed PMID: 32817606; PubMed Central PMCID:
577 PMCPMC7439980.

578 39. Evelyn B, Toigo T, Banks D, Pohl D, Gray K, Robins B, et al. Participation of
579 racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular

entities approved 1995-1999. J Natl Med Assoc. 2001;93(12 Suppl):18s-24s. Epub
2002/01/19. PubMed PMID: 11798060; PubMed Central PMCID: PMCPMC2719997.

40. Seidler EM, Keshaviah A, Brown C, Wood E, Granick L, Kimball AB. Geographic
distribution of clinical trials may lead to inequities in access. Clin Invest. 2014;4(4):373-
80.

41. Administration UFaD. CLINICAL MEMORANDUM - COVID-19 Convalescent
Plasma Silver Spring2020. Available from: <https://www.fda.gov/media/141480/download>.

42. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al.
Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med.
2020;383(19):1813-26. Epub 2020/05/24. doi: 10.1056/NEJMoa2007764. PubMed
PMID: 32445440; PubMed Central PMCID: PMCPMC7262788.

43. Rojek AM, Horby PW. Modernising epidemic science: enabling patient-centred
research during epidemics. BMC Med. 2016;14(1):212. Epub 2016/12/19. doi:
10.1186/s12916-016-0760-x. PubMed PMID: 27989237; PubMed Central PMCID:
PMCPMC5165716.

Supplemental Table 1. Characteristics of acute care facilities and hospitals that enrolled patients with COVID-19 in the US Expanded Access Program to convalescent plasma.

Site Overview	
	Overall
Part of a Health System	1,803/2,194 (82.2)
Micro/Metropolitan	
Metropolitan	1,918/2,232 (85.9)
Micro/Metropolitan	244/2,232 (10.9)
None	70/2,232 (3.1)
Urban/Rural Classification	1,494/2,100 (71.1)
Sole Community Hospital	199/2,194 (9.1)
Rural Referral Center	351/2,194 (16.0)
Teaching Hospital	1,024/2,061 (49.7)
Major Teaching Hospital (member of COTH)	447/2,061 (21.7)
University Affiliated	1,062/2,194 (48.4)

Supplemental Table 2. Pre-existing conditions and cardiovascular and lung disease history of patients with COVID-19 who enrolled in the US Expanded Access Program to convalescent plasma.

Pre-Existing Conditions	
	Overall
Pre-Existing Conditions	
History of lung disease (ex. COPD, lung cancer)	7,225/44,081 (16.4)
Cancer other than above	2,068/44,081 (4.7)
History of cardiovascular conditions	21,673/44,081 (49.2)
Obesity	14,608/44,081 (33.1)
HIV positive	351/44,081 (0.8)
HCV positive (Hepatitis C)	375/44,081 (0.9)
On immunosuppressive therapy	1,631/44,081 (3.7)
Diabetes	17,612/44,081 (40.0)
History of Cardiovascular Disease	
Stroke	1,493/19,490 (7.7)
Coronary Artery Disease (including prior myocardial infarct or MI)	4,019/19,490 (20.6)
Valvular Heart Disease	501/19,490 (2.6)
Peripheral Vascular Disease	702/19,490 (3.6)
Hypertension	16,894/19,490 (86.7)
Arrhythmias	2,199/19,490 (11.3)
Heart Failure	2,413/19,490 (12.4)
Myocarditis	15/19,490 (0.1)
Cardiomyopathy	586/19,490 (3.0)
Prior Coronary Artery Bypass Graft (CABG)	688/19,490 (3.5)
Other	1,959/19,490 (10.1)
None	130/19,490 (0.7)
History of Lung Disease	
COPD (chronic bronchitis, emphysema)	2,403/21,193 (11.3)
Lung cancer	160/21,193 (0.8)
Asthma	1,301/21,193 (6.1)
None	112/21,193 (0.5)
Other lung-related conditions	744/21,193 (3.5)